Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BMY · as of Sep 30, 2025
Ownership Breakdown
2,364
Institutional Holders
▼ 24 vs Q2
$71.53B
Total Inst. Value
▼ $4.50B vs Q2
2.04B
Shares Outstanding
freeFloat 99.68%
1.59B
13F Shares Held
▼ 59.00M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BMY largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 195.98M | 9.63% | 9.63% | $8.84T | Nov 7, 2025 | ▲ 1.06M |
BLACKROCK, INC. pharmaceutical preparations | 175.52M | 8.62% | 8.62% | $7.92T | Nov 12, 2025 | ▲ 3.29M |
STATE STREET CORP pharmaceutical preparations | 96.60M | 4.75% | 4.75% | $4.36T | Nov 14, 2025 | ▲ 1.86M |
JPMORGAN CHASE & CO pharmaceutical preparations | 86.18M | 4.23% | 4.23% | $3.89T | Nov 26, 2025 | ▼ 17.78M |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC pharmaceutical preparations | 73.04M | 3.59% | 3.59% | $3.29T | Nov 10, 2025 | ▲ 2.24M |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 46.55M | 2.29% | 2.29% | $2.10T | Nov 12, 2025 | ▲ 377.6K |
AMERIPRISE FINANCIAL INC pharmaceutical preparations | 32.47M | 1.60% | 1.60% | $1.46T | Nov 14, 2025 | ▼ 105.8K |
CAPITAL INTERNATIONAL INVESTORS pharmaceutical preparations | 32.39M | 1.59% | 1.59% | $1.46T | Nov 13, 2025 | ▼ 33.78M |
MORGAN STANLEY pharmaceutical preparations | 27.87M | 1.37% | 1.37% | $1.26T | May 27, 2026 | ▲ 1.06M |
NORTHERN TRUST CORP pharmaceutical preparations | 24.62M | 1.21% | 1.21% | $1.11T | Nov 14, 2025 | ▼ 257.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
25
Increased
+40.63M shares0
New Positions
first time holders25
Decreased
−87.09M shares0
Sold Out
fully exitedNet shares change (top 50)
46.45M
+40.63M / −87.09M
Net new holders
+0
0 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BMY insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
3
Buy transactions
9
Sell transactions
0.33
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Short Bartie Wendy EVP, Corporate Affairs | Jun 3, 2026 | Tax Withhold | 3,876 | $54.72 | $212.1K | 12.1K | Form 4 ↗ |
Lenkowsky Adam EVP, Chief Commercial Officer | May 1, 2026 | J-Other | 203 | — | — | 20.3K | Form 4 ↗ |
Lenkowsky Adam EVP, Chief Commercial Officer | May 1, 2026 | Tax Withhold | 599 | $58.22 | $34.9K | 19.7K | Form 4 ↗ |
Shanahan Karin EVP, Chief Supply Chain & Ops | Apr 1, 2026 | Tax Withhold | 1,692 | $61.73 | $104.4K | 25.9K | Form 4 ↗ |
Elkins David V EVP, Chief Financial Officer | Apr 1, 2026 | Sale | 25,519 | $61.60 | $1.57M | 163.7K | Form 4 ↗ |
Elkins David V EVP, Chief Financial Officer | Apr 1, 2026 | Sale | 4,481 | $62.05 | $278.0K | 159.2K | Form 4 ↗ |
YALE PHYLLIS R director | Mar 31, 2026 | Award | 577.082 | — | — | 43.9K | Form 4 ↗ |
Samuels Theodore R. II director | Mar 31, 2026 | Award | 845.012 | — | — | 68.7K | Form 4 ↗ |
Rice Derica W director | Mar 31, 2026 | Award | 638.912 | — | — | 40.0K | Form 4 ↗ |
McMullen Michael R. director | Mar 31, 2026 | Award | 577.082 | — | — | 15.6K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Bristol-Myers Squibb Company (BMY) is primarily owned by institutional investors, who hold approximately 77.7% of total shares outstanding. Company insiders own approximately 0.32%, while retail and public investors account for the remaining 22.03%.
The largest institutional shareholder of Bristol-Myers Squibb Company is VANGUARD GROUP INC, holding approximately 195.98 million shares — equal to 9.63% of outstanding shares — as of September 30, 2025.
A total of 2,364 institutional investors currently hold BMY stock, with a combined institutional value of approximately $71.53 billion as of the most recent 13F filing period.
Frequently asked questions
BMY ownershipBristol-Myers Squibb Company (BMY) is primarily owned by institutional investors, who hold approximately 77.7% of shares. The largest shareholder is VANGUARD GROUP INC with a 9.63% stake. Company insiders hold 0.32%. Data sourced from SEC Form 13F as of September 30, 2025.